Tat-PTD-Modified Oncolytic Adenovirus Driven by the SCG3 Promoter and ASH1 Enhancer for Neuroblastoma Therapy

Jin, Chuan; Yu, Di; Čančer, Matko; Nilsson, Berith; Leja, Justyna; Essand, Magnus

doi:10.1089/hum.2012.132

Cited by 9 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Electrostatic formation of complexes between negatively charged adenoviral particles and positively charged CPPs, such as Tat, penetratin, poly-arginine and Pep1, led to 100-fold greater transduction of CAR-negative cells compared to unmodified adenovirus, though again only in vitro [77]. In contrast, oncolytic adenovirus-serotype 5 modified to express an SCG3 promoter/ASH1 enhancer driven E1A gene expression, further modified to express Tat in the viral capsid protein, led to delays in tumor growth and prolonged survival of nude mice harboring subcutaneous human neuroblastoma xenografts [78]. In a very interesting application, brain-derived neurotrophic factor was fused with Tat and another CPP, HA2, and packaged into adeno-associated virus.…”

Section: Viral Vectorsmentioning

confidence: 99%

Cell Penetrating Peptides, Novel Vectors for Gene Therapy

2020

View full text Add to dashboard Cite

Cell penetrating peptides (CPPs), also known as protein transduction domains (PTDs), first identified ~25 years ago, are small, 6–30 amino acid long, synthetic, or naturally occurring peptides, able to carry variety of cargoes across the cellular membranes in an intact, functional form. Since their initial description and characterization, the field of cell penetrating peptides as vectors has exploded. The cargoes they can deliver range from other small peptides, full-length proteins, nucleic acids including RNA and DNA, liposomes, nanoparticles, and viral particles as well as radioisotopes and other fluorescent probes for imaging purposes. In this review, we will focus briefly on their history, classification system, and mechanism of transduction followed by a summary of the existing literature on use of CPPs as gene delivery vectors either in the form of modified viruses, plasmid DNA, small interfering RNA, oligonucleotides, full-length genes, DNA origami or peptide nucleic acids.

show abstract

Section: Viral Vectorsmentioning

confidence: 99%

Cell Penetrating Peptides, Novel Vectors for Gene Therapy

2020

View full text Add to dashboard Cite

show abstract

“…SCG3 is highly expressed in endocrine and neural tissues. [12] It has been reported in prostate cancer research that the study of the mechanism of cell differentiation has revealed the secretion of SCG3 in the peripheral blood of patients with prostate cancer, suggesting that SCG3 can be used as an indicator for detecting the degree of differentiation of tumor cells. For the detection of changes in prostate cancer and future disease prognosis.…”

Section: Discussionmentioning

confidence: 99%

The research of Secretogranin III in periperal blood and vitreous of diabetic retinopathy

Jiao¹,

Sun²,

Wang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Secretory granulin III (SCG3) is a member of the secretory granule protein family that regulates the production of secretory granules. SCG3 has a role in reducing retinal vascular leakage and neovascularization in an animal model of diabetic retinopathy. This study aimed to study SCG3 in periperal blood and vitreous of human. Methods ： (1) Collecting diabetic retinopathy(DR) patients required vitrectomy, and patients requiring vitrectomy for other non-diabetic factors, retaining some of the vitreous, ELISA was used to detect SCG3 in vitreous. The grouping was divided according to the patients’ blood lipids, BMI (Body Mass Index, BMI) and analyzed. (2) Collecting peripheral blood of DR and non-diabetic patients, ELISAwas performed. Results: (1) A total of 43 cases with DR were collected, and 34 cases non-diabetic patients were collected. SCG3 in DR patients was higher than that of non-diabetic. After refinement grouping, it was found that SCG3 with DR and hyperlipidemia was higher than that of non-diabetic patients without hyperlipidemia. SCG3 with DR and hyperlipidemia was higher than that of DR patients without hyperlipidemia. SCG3 of patients with DR and high BMI was higher than that of non-diabetic with normal BMI. SCG3 with DR and high BMI was higher than that of non-diabetic patients with normal BMI. (2) SCG3 in plasma was minimal or could not be detected. Conclusion： In DR patients, up-regulation of vitreous SCG3 may be closely related to the pathogenesis of DR. However, SCG3 is almost difficult to detect in normal vessel vasculature, which may highlight its advantages in using anti-SCG3 drugs in babies and children in future.

show abstract

“…Although AdC7 has some advantages over AdHu5 as oncolytic viruses, AdC7 without modification could not address the AdHu5 drawback of nonselectivity in infecting target cells. This problem might be overcame by attempts to genetically alter the fiber protein [ 30 ] or to insert some peptides into the hexon region [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

A novel oncolytic adenovirus based on simian adenovirus serotype 24

et al. 2017

View full text Add to dashboard Cite

Among the oncolytic virotherapy, an emerging treatment for tumor, adenoviruses are widely used at present in preclinical and clinical trials. Traditionally, oncolytic adenoviruses were developed based on the human adenovirus serotype 5 (AdHu5). However, AdHu5 has the drawbacks of preexisting anti-AdHu5 immunity in most populations, and extensive sequestration of Adhu5 by the liver through hexon, blood coagulation factor X (FX), and FX receptor interactions. To tackle these problems, we explored a novel oncolytic adenovirus AdC7-SP/E1A-ΔE3 for cancer treatment. AdC7-SP/E1A-ΔE3 was constructed by replacing the E1A promoter with tumor specific promoter survivin promoter and deleting E3 region using direct cloning methods based on simian adenovirus serotype 24 (namely AdC7). We showed that AdC7-SP/E1A-ΔE3 significantly killed tumor cell lines NCI-H508 and Huh7, and inhibited tumor growth in both NCI-H508 and Huh7 xenograft tumor models. Importantly, AdC7-SP/E1A-ΔE3 exhibited the antitumor efficacy via systemic administration. Mechanistically, infected cells were killed by AdC7-SP/E1A-ΔE3 via the p53-independent mitochondrial apoptosis pathway in which phosphorylation of BAD markedly declined and the expresses of Bik significantly went up. Therefore, AdC7-SP/E1A-ΔE3 is a promising candidate for liver and colon tumor treatment.

show abstract

Tat-PTD-Modified Oncolytic Adenovirus Driven by the SCG3 Promoter and ASH1 Enhancer for Neuroblastoma Therapy

Cited by 9 publications

References 27 publications

Cell Penetrating Peptides, Novel Vectors for Gene Therapy

Cell Penetrating Peptides, Novel Vectors for Gene Therapy

The research of Secretogranin III in periperal blood and vitreous of diabetic retinopathy

A novel oncolytic adenovirus based on simian adenovirus serotype 24

Contact Info

Product

Resources

About